The Actionable Hereditary Cancer Panel is a specialized genetic test designed to identify inherited mutations in clinically significant cancer-related genes linked to preventable or manageable cancer risks. It focuses on genetic changes for which established medical guidelines, targeted surveillance, or preventive interventions are available. The test helps individuals understand their inherited cancer susceptibility, supports early detection strategies, guides personalized treatment decisions, and enables family members to take proactive healthcare measures when necessary.
The panel may include BRCA1, BRCA2, TP53, APC, PALB2, MLH1, MSH2, CHEK2, and other clinically actionable genes.
This panel specifically focuses on genes with established clinical management guidelines, making the results directly useful for preventive and treatment-related decisions.
Certainly, individuals without cancer but with significant family history may undergo testing to evaluate inherited cancer susceptibility and future risk.
The panel focuses on genetic findings with available medical guidelines, allowing healthcare providers to recommend preventive measures, surveillance, or personalized treatment strategies.
The test commonly evaluates hereditary risks for breast, ovarian, colorectal, prostate, pancreatic, and several other inherited cancers.
Yes, genetic counseling helps individuals understand test implications, possible outcomes, family risks, and appropriate follow-up care recommendations.
...
Didn't recieved OTP Yet? Resend OTP